


Cite this: *RSC Adv.*, 2019, 9, 40628

Received 28th October 2019
Accepted 2nd December 2019

DOI: 10.1039/c9ra08831h

rsc.li/rsc-advances

Diterpenoids from *Isodon rubescens* and their nitric oxide production inhibitory activity†

Chumao Wen,^{‡a} Su Chen,^{‡a} Fang Yuan,^a Xiangming Liu,^a Fajun Song,^c Zhinan Mei,^b Xiaofei Yang^{*a} and Guangzhong Yang^{ib} ^{*b}

Six new *ent*-kaurane diterpenoids, isodonrubescins A–F (1–6), together with twenty-five known *ent*-kaurane diterpenoids (7–31), a known *ent*-atisane diterpenoid (32), and two known *ent*-abietane diterpenoids (33–34), were isolated from *Isodon rubescens*. Their structures were established by means of extensive MS and NMR data analysis. Among the all isolates, compound 7 was found in a natural product for the first time, and *ent*-atisane diterpenoid was discovered from *I. rubescens* in Hubei Province, P. R. China for the first time. Furthermore, all the isolated compounds were tested for their NO production inhibitory activity in LPS stimulated RAW264.7 cells. Compounds 7–9, 12, 13, 16, and 17 displayed NO production inhibitory activities with IC₅₀ values ranging from 1.36 to 18.25 μM, respectively.

1. Introduction

The genus *Isodon*, comprising about 150 different species of under-shrubs, sub-undershrubs, or perennial herbs, is a cosmopolitan and important genus of the Lamiaceae family. It is widely distributed in tropical and subtropical Asia. Previous studies have shown that they are rich sources of diterpenoids with diverse structural scaffolds, such as *ent*-kauranes, *ent*-abietanes, *ent*-atisanes, and have a range of biological activities.^{1–3}

Isodon rubescens is a perennial herb distributed widely in Henan, Guizhou, Hebei, Jiangxi, Hubei, and some other provinces of P. R. China.⁴ It has attracted great attention due to the traditional uses in folk medicine for the treatment of respiratory and gastrointestinal bacterial infections, inflammation, and cancer.^{5–8} Oridonin, an important *ent*-kaurane from *I. rubescens* showed the anti-tumor and anti-inflammatory activities. Previous studies have demonstrated that it exhibits anti-tumor effects on human cancer cells, such as HepG2, SGC-7901, MCF-7, mainly by blocking the cell cycle, inducing apoptosis and autophagy of tumor cells, and shows anti-inflammatory effects by inhibiting the expression of inflammatory factors through nuclear factor-kappa B (NF-κB) signal pathway.^{9,10} In addition,

previous investigations on the chemical constituents of *I. rubescens* collected from different provinces, P. R. China revealed that they contained different structure types of diterpenoids. For example, the chemical constituents of *I. rubescens* collected from Guizhou Province were mainly 6,7-*seco*-*ent*-kaurane diterpenoids, however, 7,20-epoxy-*ent*-kaurane diterpenoids were main chemical constituents of *I. rubescens* collected from Henan Province.^{11,12} Furthermore, the chemical constituents of *I. rubescens* collected from Hubei Province have not been extensively investigated, only 16 new diterpenoids have been reported, including diterpene alkaloids with an aza-*ent*-kaurane skeleton.^{13–17} Therefore, in order to fully understand the active constituents of *I. rubescens* from different regions, a reinvestigation of *I. rubescens* collected from Badong county, Hubei Province was undertaken in the hope of discovering diterpenoids with interesting structures and biological activities. As a result, six new diterpenoids (1–6), together with twenty-five known *ent*-kaurane diterpenoids (7–31), a known *ent*-atisane diterpenoid (32) and two known *ent*-abietane diterpenoids (33–34) were isolated from this plant, and it should be noted that compounds 10, and 13–17 have been reported in our previous work.¹⁸ Herein we reported the isolation, structural elucidation of six new diterpenoids and biological activities of all isolated compounds (Fig. 1).

2. Results and discussion

Compound 1 was obtained as colorless needle crystals, and its molecular formula was determined to be C₂₂H₃₂O₇ based on the HR-ESI-MS at *m/z* 431.20383 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.20402), indicating of seven degrees of unsaturation. The ¹H NMR spectra (Table 1) of 1 revealed the presence of two singlet methyls [δ_H 0.96 (s), 0.93 (s)] and two methoxy groups [δ_H 3.19

^aCollege of Biomedical Engineering, South-Central University for Nationalities, Wuhan 430074, P. R. China. E-mail: sunlittletfly@hotmail.com; Fax: +86 27 6784 1196; Tel: +86 27 6784 1196






^bSchool of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan 430074, P. R. China. E-mail: yanggz888@126.com

^cCollege of Life Science, South Central University for Nationalities, Wuhan 430074, P. R. China


† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra08831h

‡ These authors contributed equally to this work.







28




31




	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
3	α-OH	H	OH	OH	H	OAc
4	α-OH	H	OAc	H	OH	OH
5	H	β-OH	OH	H	OH	OAc
13	α-OH	H	OH	H	OH	=O
14	H	α-OH	OAc	H	OH	OAc
15	α-OH	H	OH	H	OH	OAc
16	H	β-OAc	OAc	H	OH	OAc
17	α-OAc	H	OH	H	OH	=O
18	α-OH	H	OH	OH	H	OH
19	α-OH	H	OAc	OH	H	OH
20	H	H	OAc	OH	OH	OH
21	α-OH	H	OH	OH	H	=O
22	β-OH	H	OH	H	H	OH
23	H	α-OH	OH	H	OH	OH
24	H	α-OH	OAc	H	OH	OH
25	H	β-OH	OAc	H	OH	OAc




29




32




6



26



27



30





Fig. 1 Structures of compounds 1–34.

(s), 3.15 (s)], one oxygenated methylene [δ_{H} 4.32 (d, $J = 9.6$ Hz), 4.28 (d, $J = 9.6$ Hz)], three oxygenated methines [δ_{H} 4.89 (m), 5.03 (s), 4.46 (m)]. Its ^{13}C NMR and DEPT spectra (Table 2) exhibited 22 carbon signals, including two methoxy groups at δ_{C} 54.8 and δ_{C} 59.0, two oxygenated methylenes at δ_{C} 74.5 and δ_{C}

71.8, two oxygenated methines at δ_{C} 76.9 and δ_{C} 64.8, one hemiacetal group at δ_{C} 109.7, one δ -lactone carbonyl group at δ_{C} 171.3, one carbonyl group at δ_{C} 212.9 and three quaternary carbons at δ_{C} 31.7, δ_{C} 57.7 and δ_{C} 51.2, which implied a 6,7-*seco*-kaurane skeleton. Detailed analysis of the NMR data of 1



Table 1 ^1H -NMR data of compounds **1–6** in $\text{C}_5\text{D}_5\text{N}$ (600 MHz, δ in ppm, J in Hz)

No.	1	2	3	4	5	6
1	4.89 (m)	4.92 (dd, 6.9, 10.5)	4.35 (m)	3.74 (m)	1.74–1.86 (m)	6.38 (dd, 2.4, 10.8)
2	1.87 (m)	1.91 (m)	1.96 (m)	1.86 (m)	2.07 (m); 1.09 (d, 12.6)	5.73 (ddd, 1.8, 6.0, 10.2)
3	1.31 (m)	1.37 (m); 1.32 (m)	1.51 (m); 1.42 (m)	1.34 (m)	3.75 (s)	1.94 (overlap); 1.77 (dd, 6.0, 16.8)
4						
5	3.48 (s)	3.27 (s)	1.74 (d, 5.4)	1.77 (d, 6.6)	2.44 (d, 6.6)	2.16 (d, 6.6)
6	5.03 (s)	5.76 (s)	4.24 (dd, 5.4, 3.6)	5.86 (d, 6.6)	4.33 (dd, 2.4, 6.6)	4.31 (dd, 4.8, 6.6)
7						
8						
9	2.65 (m)	2.93 (d, 10.8)	2.82 (d, 9.6)	2.92 (dd, 6.0, 12.9)	2.84 (overlap)	2.88 (dd, 1.2, 9.6)
10						
11	4.46 (m)	4.55 (dd, 8.7, 18.9)	4.73 (m)	2.31 (m); 1.91 (m)	1.54 (m); 1.23 (m)	4.58 (m)
12	2.91 (m); 1.60 (dd, 9.0, 13.8)	2.95 (m); 1.58 (dd, 9.0, 14.4)	2.86 (m); 1.91 (m)	2.42 (m); 1.73 (m)	2.32 (m); 1.61 (m)	2.96 (m); 1.91 (overlap)
13	2.61 (dd, 4.2, 9.6)	2.68 (dd, 3.6, 9.6)	2.72 (dd, 9.6, 3.6)	2.87 (d, 9.6)	2.84 (overlap)	2.76 (dd, 5.4, 10.4)
14	2.68 (m); 2.33 (dd, 4.2, 12.0)	2.72 (d, 12.0); 2.39 (dd, 3.9, 12.3)	2.22 (d, 12.6); 2.17 (dd, 12.6, 4.2)	5.15 (overlap)	5.08 (s)	2.19 (dd, 4.8, 12.6); 2.01 (d, 12.6)
15			6.55 (s)	5.57 (d, 2.4)	6.93 (s)	5.20 (overlap)
16	2.67 (m)	2.63 (br t, 5.4)				
17	3.60 (m); 3.52 (dd, 4.2, 9.0)	3.61 (m)	5.29 (s); 5.12 (s)	5.69 (s); 5.40 (s)	5.41 (s); 5.22 (overlap)	5.51 (s); 5.22 (overlap)
18	0.96 (s)	0.98 (s)	1.24 (s)	0.92 (s)	1.57 (s)	1.20 (s)
19	0.93 (s)	0.98 (s)	1.21 (s)	1.22 (s)	1.21 (s)	1.12 (s)
20	4.32 (d, 9.6); 4.28 (d, 9.6)	4.42 (d, 9.0); 4.30 (d, 9.0)	4.81 (d, 9.6); 4.50 (d, 9.6)	4.86 (d, 9.6); 4.46 (d, 9.6)	4.36 (d, 9.6); 4.05 (d, 9.6)	4.36 (d, 9.6); 4.16 (dd, 1.2, 9.6)
OAc			2.20 (s)	2.21 (s)	2.28 (s)	
OMe	3.19 (s)					
OMe	3.15 (s)					
OCH_2CH_3						
HO-1		3.32 (m); 1.07 (t, 7.2)	6.75 (d, 4.2)	5.97 (d, 4.2)	6.00 (s)	
HO-3					5.91 (s)	8.17 (d, 4.2)
HO-6		9.11 (s)	6.25 (d, 3.0)		8.01 (s)	8.07 (s)
HO-7			7.91 (s)	8.31 (s)		5.77 (br s)
HO-11	5.75 (s)	7.24 (overlap)	7.10 (d, 6.0)		8.06 (s)	
HO-14				8.01 (s)		
HO-15				4.40 (d, 3.0)		6.84 (d, 2.4)

Table 2 ^{13}C NMR data of compounds **1–6** in $\text{C}_5\text{D}_5\text{N}$ (150 MHz, δ in ppm)

No.	1	2	3	4	5	6
1	76.9(d)	77.1(d)	74.2(d)	73.5(d)	26.4(t)	130.2(d)
2	24.2(t)	24.4(t)	28.8(t)	30.7(t)	24.6(t)	125.3(d)
3	37.1(t)	37.3(t)	40.5(t)	39.1(t)	74.8(d)	41.4(t)
4	31.7(s)	31.9(s)	34.5(s)	34.2(s)	38.7(s)	32.7(s)
5	53.1(d)	54.2(d)	57.3(d)	55.5(d)	50.3(d)	57.5(d)
6	109.7(d)	102.5(d)	74.5(d)	75.3(d)	73.5(d)	74.3(d)
7	171.3(s)	171.4(s)	97.2(s)	98.8(s)	100.1(s)	97.6(s)
8	57.7(s)	57.4(s)	53.1(s)	53.8(s)	53.0(s)	53.8(s)
9	52.6(d)	52.7(d)	52.1(d)	45.7(d)	46.5(d)	50.8(d)
10	51.2(s)	51.3(s)	42.9(s)	41.7(s)	35.9(s)	39.4(s)
11	64.8(d)	63.9(d)	63.6(d)	18.8(t)	15.4(t)	62.8(d)
12	42.1(t)	41.9(t)	41.4(t)	33.0(t)	32.4(t)	45.7(t)
13	32.2(d)	32.1(d)	37.7(d)	46.2(d)	46.1(d)	37.2(d)
14	34.3(t)	34.1(t)	28.9(t)	76.4(d)	76.4(d)	28.0(t)
15	212.9(s)	213.1(s)	75.3(d)	73.4(d)	74.2(d)	75.9(d)
16	58.5(d)	58.8(d)	160.7(s)	161.5(s)	160.0(s)	161.7(s)
17	71.8(t)	69.5(t)	107.7(t)	110.2(t)	110.6(t)	107.9(t)
18	33.1(q)	33.3(q)	33.8(q)	32.0(q)	29.8(q)	31.4(q)
19	23.6(q)	23.4(q)	23.3(q)	22.2(q)	23.8(q)	22.7(q)
20	74.5(t)	74.0(t)	64.7(t)	64.1(t)	67.0(t)	66.8(t)
OAc			171.4(s)	169.6(s)	171.6(s)	
			22.3(q)	21.7(q)	22.5(q)	
OMe	54.8(q)					
OMe	59.0(q)					
OCH ₂ CH ₃		66.9(t)				
		15.5(q)				

indicated that **1** is structurally related to dayecrystal D.¹⁹ The significant difference between them was the change of the chemical shift of C-12 from δ_{C} 42.1 in **1** to δ_{C} 33.1 in the latter, which was caused by a γ -gauche shielding effect between 16-methoxymethyl group and H-12 α . Therefore, it can be deduced that the methoxymethyl group at C-16 in **1** was β -oriented. The location of the methoxymethyl group at C-16 was revealed by the HMBC correlation of OMe (δ_{H} 3.15) with C-17 (δ_{C} 71.8) and the ^1H - ^1H COSY correlations (Fig. 2) of H₂-17 (δ_{H} 3.60, δ_{H} 3.52) with H-16 (δ_{H} 2.67). The ROESY (Fig. 3) correlations of H-16 with H-12 α (δ_{H} 1.60), of H-12 β (δ_{H} 2.91) with H-13 β and H-11 β confirmed the β -orientation of the methoxymethyl group. Consequently, the structure of **1** was assigned as 11 α -hydroxy-6 β -methoxy-16 β -methoxymethyl-6,7-*seco*-6,20-exoxy-1 α ,7-olide-*ent*-kaur-15-one, and named as isodonrubescins A.

Compound **2** was isolated as colorless crystals (MeOH), and its molecular formula was the same as **1**, as established to be $\text{C}_{22}\text{H}_{32}\text{O}_7$ by HR-ESI-MS at m/z 431.20407 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{22}\text{H}_{32}\text{O}_7\text{Na}$, 431.20402) and ^{13}C NMR data. A comparison of the NMR data of **2** (Tables 1 and 2) with those of **1** suggested that compound **2** had a 6,7-*seco-ent*-kaurane skeleton as **1**, except for the disappearance of two methoxyl signal and the presence of an additional ethoxyl signal. The location of the ethoxyl group at C-17 was revealed by the HMBC correlations of H₂-17 (δ_{H} 3.61) with the carbon (δ_{C} 66.9) of the ethoxyl group. In addition, the chemical shift of C-6 was shifted upfield from δ_{C} 109.7 in **1** to δ_{C} 102.5 in **2** due to the change of the substituent at C-6 from a methoxyl group in **1** to a hydroxyl group in **2**. The

relative stereochemistry of **2** was consistent with those of **1** and was ensured by the ROESY correlations (Fig. 3). Accordingly, the structure of compound **2** was established as 6 β ,11 α -dihydroxy-16 β -ethoxymethyl-6,7-*seco*-6,20-exoxy-1 α ,7-olide-*ent*-kaur-15-one and given the name isodonrubescins B.

Compound **3** was exhibited to have the molecular formula $\text{C}_{22}\text{H}_{32}\text{O}_7$ by HR-ESI-MS (m/z 431.20288 [$\text{M} + \text{Na}$]⁺, calcd 431.20402). The ^1H -NMR spectra (Table 1) of **3** established the existence of three single methyls [δ_{H} 1.24 (s), 1.21 (s), 2.20 (s)], one olefinic methylene [δ_{H} 5.29 (s), 5.12 (s)], one oxygenated methylene [δ_{H} 4.81 (d, $J = 9.6$ Hz), 4.50 (d, $J = 9.6$ Hz)], four oxygenated methines [δ_{H} 4.35 (m), 4.24 (dd, $J = 5.4, 3.6$ Hz), 4.73 (m), 6.55 (s)]. The methyl at δ_{H} 2.20 (3H, s) and the carbonyl group at δ_{C} 171.4 in the NMR spectrum suggested the presence of an acetoxyl group in **3**. Apart from the acetoxyl group, there were 20 carbon resonances, consisting of two methyls, six methylenes (one oxygenated carbon at δ_{C} 64.7 and one olefinic carbon at δ_{C} 107.7), seven methines (four oxygenated carbons at δ_{C} 74.2, δ_{C} 74.5, δ_{C} 63.6 and δ_{C} 75.3, respectively), and five quaternary carbons (one hemiacetal group at δ_{C} 97.2 and one olefinic carbon at δ_{C} 160.7). The above-mentioned data suggested compound **3** to be a 7,20-epoxy-*ent*-kaurane diterpenoid. Comparison of the NMR data of **3** with those of hebeirubescins K²⁰ indicated that their structures were closely related. The only structural difference between them was that the hydroxyl group at C-15 in the latter was replaced by an acetoxyl group in **3**, which can be deduced by the change of the chemical shift of H-15 from δ_{H} 5.06 in the latter to δ_{H} 6.55 in **3** and was further confirmed by the HMBC correlations (Fig. 2) from H-15 to C-16 (δ_{C} 160.7) and OAc (δ_{C} 171.4). The remaining structure was corroborated by the HMBC experiment.

The relative configuration of **3** was revealed by analysis of the ROESY spectrum (Fig. 3), in which the correlations of H-6/H₃-19 α (δ_{H} 1.21), H-11/H-12 α (δ_{H} 2.86)/H-13 α (δ_{H} 2.72), H-15/H-14 β (δ_{H} 2.17)/H-13 α were clearly observed, indicating that HO-6, HO-11, and AcO-15 were β -orientation. Correlations of H-1/H-5 β assigned HO-1 to be α -oriented. Thus, Compound **3** was determined as 1 α ,6 β ,11 β -trihydroxy-15 β -acetoxyl-7,20-exoxy-*ent*-kaur-16-ene, and named as isodonrubescins C.

Compound **4** had the same molecular formula $\text{C}_{22}\text{H}_{32}\text{O}_7$ as that of **3**, which was established by HR-ESI-MS at m/z 431.20404 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{22}\text{H}_{32}\text{O}_7\text{Na}$, 431.20402). Its ^1H and ^{13}C NMR spectra (Tables 1 and 2) showed that compound **4** possessed the same 7,20-epoxy-*ent*-kaurane skeleton as that of **3**. A comparison of the NMR data of **4** (Tables 1 and 2) with those of enmenol²¹ disclosed that **4** was a 6-acetyl derivative of enmenol. The key HMBC correlation (Fig. 2) from H-6 (δ_{H} 5.86) to OAc (δ_{C} 169.6) in **4** confirmed this conclusion. Furthermore, the ^1H - ^1H COSY correlations (Fig. 2) of H-1 (δ_{H} 3.74) with H₂-2 (δ_{H} 1.86), of H-14 (δ_{H} 5.15) with H-13 (δ_{H} 2.87) and the HMBC correlations of H-15 (δ_{H} 5.57) with C-16 (δ_{C} 161.5) and C-17 (δ_{C} 110.2) indicated that three hydroxyl groups were located at C-1, C-14 and C-15 respectively. The relative configuration of **4** was assigned by the ROESY correlations (Fig. 3) of H-1/H-9 β (δ_{H} 2.92), H-6/H₃-19 α (δ_{H} 1.22), HO-15 (4.40)/H-9 β (2.92), which revealed the α -orientation of HO-1 and the β -orientation of AcO-6, HO-14, HO-15. Therefore, the structure of **4** was elucidated as






Fig. 2 Key HMBC and ^1H - ^1H COSY correlations of compounds 1–6.

$1\alpha,14\beta,15\beta$ -trihydroxy-6 β -acetoxyl-7,20-exoxy-ent-kaur-16-ene, and given the name isodonrubescins D.

Compound 5 was obtained as a white amorphous powder with a molecular formula of $\text{C}_{22}\text{H}_{32}\text{O}_7$ as assigned by HR-ESI-MS (m/z 431.20380 [$\text{M} + \text{Na}$] $^+$, calcd 431.20402). Its ^1H and ^{13}C NMR data (Tables 1 and 2) resembled those of hikiokoshins G,²² suggesting that 5 had the same carbon skeleton as that of hikiokoshins G. The difference between them was that hikiokoshins G had two acetoxyl groups while compound 5 only possessed one acetoxyl group, and in the HMBC spectrum of 5 (Fig. 2), the cross-peak of H-15 with OAc (δ_{C} 171.6) indicated that the acetoxyl group was located at C-15. Thus, 5 was a 6-deacetyl derivative of hikiokoshins G, this conclusion was further supported by the change of the chemical shift of H-6 from δ_{H} 5.98 in hikiokoshins G to δ_{H} 4.33 in 5. The relative stereochemistry of 5 was consistent with those of hikiokoshins G, and was confirmed by the ROESY analysis (Fig. 3). Accordingly, compound 5 was established as $3\beta,6\beta,14\beta$ -trihydroxy-15 β -acetoxyl-7,20-exoxy-ent-kaur-16-ene, and named as isodonrubescins E.

Compound 6 had the molecular formula of $\text{C}_{20}\text{H}_{28}\text{O}_5$ as determined by its HR-ESI-MS (m/z 349.20029 [$\text{M} + \text{H}$] $^+$, calcd 349.20095) and ^{13}C NMR data, indicating seven degrees of unsaturation. The ^1H NMR and ^{13}C NMR spectra (Tables 1 and Table 2) of 6 implied that compound 6 was a 7,20-epoxy-ent-kaurane diterpenoid. However, unlike the normal type of 7,20-epoxy-ent-kaurane diterpenoids, such as compound 3–5, a *cis*

double bond signal [δ_{H} 6.38 (dd, $J = 2.4, 10.8$ Hz), 5.73 (ddd, $J = 1.8, 6.0, 10.2$ Hz); δ_{C} 130.2, 125.3] was presented in the NMR spectra of 6, and the double bond was assigned to C-1 and C-2 by the key ^1H - ^1H COSY correlations of 6 (Fig. 2) from H-1 (δ_{H} 6.38) to H-2 (δ_{H} 5.73), from H-2 to H-3 (δ_{H} 1.94) and the key HMBC correlations (Fig. 2) from H₃-18 (δ_{H} 1.20) to C-3 (δ_{C} 41.4), from H-2 to C-10 (δ_{C} 39.4). The remaining three hydroxyl groups were respectively assigned to C-6, C-11 and C-15 by interpretation of the ^1H - ^1H COSY and HMBC correlations. The relative configuration of 6 was determined by the ROESY correlations (Fig. 3) of H-6 (δ_{H} 4.31)/H₃-19 α (δ_{H} 1.12), H-11 (δ_{H} 4.58)/H-20 (δ_{H} 4.36) and H-15 (δ_{H} 5.20)/H-13 α (δ_{H} 2.76), which suggested the β -orientation of HO-6, HO-11 and HO-15. Consequently, the structure of 6 was assigned as $6\beta,11\beta,15\beta$ -trihydroxy-7,20-exoxy-ent-kaur-1,16-diene, and given the name isodonrubescins F.

The other twenty-eight known diterpenoids (7–34) were identified by comparison of their NMR data with those reported in the literature. As a result, they were identified to be 3β -hydroxy-6 β -methoxy-6,7-*seco*-6,20-epoxy-1 $\alpha,7$ -olide-ent-kaur-16-en-15-one (7),²³ enmein (8),²⁰ rabdosin A (9),¹⁹ epinodosinol (10),¹⁸ isojaiponin A (11),²⁴ epinodosin (12),²⁵ oridonin (13),¹⁸ hubeirubescins K (14),¹⁸ neolaxiflorin U (15),¹⁸ hubeirubescins I (16),¹⁸ lasiokaurin (17),¹⁸ hebeirubescins K (18),²⁰ maoyecrystal F (19),²⁴ rabdoternin D (20),²⁶ lasiodonin (21),²⁷ enmelol (22),²⁸ rabdonervosin G (23),²⁹ rabdonervosin D (24),²⁹ hikiokoshins G (25),²² isodonhenrin E (26),³⁰ maoyecrystal L (27),²⁰ dayecrystal B (28),³¹ lushanrubescins F (29),³² ponacidin (30),³³






Fig. 3 Key ROESY correlations of compounds 1–6.

rubescensin D (31),³⁴ isorosthomin D (32),³⁵ isoadenolin M (33),³⁶ rubescensin J (34).³⁷

In addition, all the isolated compounds were assessed for their inhibitory activity against NO production in LPS stimulated RAW264.7 cells with dexamethasone as a positive control ($IC_{50} = 9.58 \mu M$). The cell viability of the tested compounds was firstly measured using CCK-8 assay to determine whether the NO production inhibitory activities were induced by the cytotoxicity. As a result, compounds 7, 9, 13, 16, and 17 exhibited obvious NO production inhibitory effects with IC_{50} values of 3.97, 2.25, 6.51, 1.48 and 1.36 μM , respectively. Compounds 8 and 12 displayed mild NO production inhibitory effects with IC_{50} values of 17.43 and 18.25 μM , respectively, while the rest of the tested compounds had no obvious NO production inhibitory activity ($IC_{50} > 20 \mu M$). In the present study, the 6,7-*seco-ent*-kaurane diterpenoids, such as 7–9 and 12 which possessed an α,β -unsaturated ketone moiety, exhibited NO production inhibitory effects, the result indicated that α,β -unsaturated ketone moiety was an essential pharmacophore. However, this conclusion did not fully be applied to 7,20-epoxy-*ent*-kaurane diterpenoids. For compounds 13, 17, 21 and 30, they shared an α,β -unsaturated ketone moiety, but compound 21 and 30 did not show the activity. This could be caused by the lack of HO-14 β in 21 and 30. Additionally, compound 16 without an α,β -unsaturated ketone moiety also exhibited obvious NO production inhibitory effects. This result further demonstrated that the α,β -unsaturated ketone moiety was not absolutely essential active center for the activity. Besides, it was interesting that compound 25 was a 3-deacetyl derivative of 16, but it did not show NO production inhibitory effect, the result suggested that 3-OAc might played an important role in the NO production inhibitory activity.

3. Experimental

3.1 General experimental procedures

Optical rotations were measured with an Autopol IV polarimeter (Rudolph Research Analytical, Hackettstown, NJ, USA). UV spectra were recorded on a UH5300 UV-VIS Double Beam spectrophotometer (Hitachi Co., Tokyo, Japan). NMR spectra were obtained on a Bruker AVANCE IIIITM 600 MHz spectrometer (Bruker, Ettlingen, Germany) in C_5D_5N with tetramethylsilane (TMS) as an internal reference standard. Chemical shifts (δ) have been given in ppm and the coupling constants (J) have been expressed in Hz. High-resolution electrospray mass spectroscopy was conducted on a Thermo Scientific Q Exactive Orbitrap LC-MS/MS System (HR-ESI-MS) (Thermo Scientific, Waltham, MA, USA). High-performance liquid chromatography (HPLC) was performed on an Ultimate 3000 HPLC system (Dionex Co., Sunnyvale, CA, USA) equipped with an Ultimate 3000 pump and Ultimate 3000 Variable Wavelength detector, as well as a semi-preparative YMC-Pack ODS-A column (250 \times 10 mm, 5 μm), column chromatography (CC) was conducted with silica gel (200–300 mesh and 300–400 mesh, Qingdao Haiyang Chemical Industry Co., Ltd., Qingdao, China). Chromatographic grade acetonitrile was purchased from Chang Tech Enterprise Co., Ltd (Taiwan, China). RAW264.7 murine macrophages were purchased from the cell bank of Chinese Academy of Sciences (Shanghai, China). Dexamethasone and lipopolysaccharides (LPS) were purchased from Sigma Chemical Co. Ltd. (St. Louis, MO, USA). Cell Counting Kit (CCK-8) was purchased from Beyotime Biotechnology (Shanghai, China). Dulbecco modified Eagle medium (DMEM) and penicillin-streptomycin solution were purchased from GE Healthcare Life Sciences (Logan, UT, USA). Fetal bovine serum (FBS) was

purchased from Gibco, Life Technologies (Grand Island, NY, USA). Reagent grade dimethyl sulfoxide (DMSO) was purchased from Vetec, Sigma Chemical Co. (St. Louis, MO, USA). The absorbance was read on a Multiskan GO microplate reader (Thermo Fisher Scientific Inc. Waltham, MA, USA).

3.2 Plant material

Isodon rubescens were collected from Badong county, Hubei Province and identified by Prof. Fajun Song, College of Life Science, South Central University for Nationalities. The voucher specimen (2016101201) was deposited in the herbarium of School of Pharmaceutical Sciences, South Central University for Nationalities.

3.3 Extraction and isolation

The air-dried and powdered parts of *I. rubescens* (11.2 kg) were extracted with 95% EtOH (25 L \times 3, each 24 h) at room temperature. The extract was filtered and evaporated to afford a crude extract (1.1 kg), which was partitioned successively with petroleum ether (P. E.) and EtOAc. The EtOAc extract (556 g) was subjected to column chromatography on a silica gel column eluting with the gradient of CHCl₃-acetone (10 : 0, 9 : 1, 8 : 2, 7 : 3, 6 : 4, 1 : 1, 3 : 7, 0 : 10) to yield eight fractions (Fr. A–Fr. H). Fr. D (123.7 g) was separated by silica gel CC (CH₂Cl₂–EtOAc, 10 : 1, 8 : 2, 6 : 4, 1 : 1) into fractions D1–D10. Fr. D6 was subjected to RP-18 CC (MeOH–H₂O, 3 : 7, 5 : 5, 7 : 3, 0 : 10) to obtain eleven fractions (Fr. D6A–Fr. D6K). Fr. D6D was purified by semi-preparative HPLC (MeOH–H₂O 33 : 67) to afford compounds **2** (15 mg, *t_R* 20.8 min) and **25** (25 mg, *t_R* 15.1 min).

Fr. E (56.3 g) was separated on RP-18 CC into six fractions (Fr. E1–Fr. E6) by eluting with MeOH–H₂O (3 : 7, 5 : 5, 7 : 3, 0 : 10). Fr. E2 and Fr. E4 was purified by recrystallizing in MeOH to afford compounds **8** (735 mg). Fr. E3 was firstly purified by a silica gel column (eluted with CH₂Cl₂–MeOH, 100 : 1, 50 : 1, 25 : 1, 15 : 1, 12 : 1 gradient) to yield nine fractions Fr. E3A–Fr. E3I. Fr. E3C was purified by recrystallizing in MeOH to afford compound **12** (8 mg), then Fr. E3A was subjected to silica gel CC (petroleum ether–EtOAc, 9 : 1, 8 : 2, 7 : 3 gradient) to obtain fractions E3A1–E3A8. Fr. E3A8 was finally purified by semi-preparative HPLC (MeOH–H₂O 43 : 57) to afford compounds **1** (10 mg, *t_R* 16.3 min) and **9** (18 mg, *t_R* 17.6 min). Similarly, compound **7** (5 mg, *t_R* 15.8 min) was obtained from Fr. E3B by semi-preparative HPLC (MeOH–H₂O, 40 : 60). Fr. E3F was successively chromatographed over silica gel CC (CH₂Cl₂–MeOH, 50 : 1, 25 : 1, 12 : 1) and semi-preparative HPLC to yield compounds **6** (1 mg, MeOH–H₂O, 36 : 64, *t_R* 41.8 min), **26** (9 mg, MeOH–H₂O, 36 : 64, *t_R* 43.3 min), **18** (25 mg, MeOH–H₂O, 45 : 55, *t_R* 22.4 min), **19** (19 mg, MeOH–H₂O, 47 : 53, *t_R* 22.3 min) and **32** (5 mg, MeOH–H₂O, 36 : 64, *t_R* 46.3 min). Fr. E6 was similarly purified with semi-preparative HPLC to yield compounds **33** (1.5 mg, CH₃CN–H₂O, 77 : 23, *t_R* 14.2 min) and **34** (7 mg, MeOH–H₂O, 79 : 21, *t_R* 15.5 min).

Fr. F (51.3 g) was separated over RP-18 CC (MeOH–H₂O, 3 : 7, 5 : 5, 7 : 3, 0 : 10 gradient) into five fractions (Fr. F1–Fr. F5), Fr. F2 and Fr. F3 was separated over repeatedly chromatographed by silica gel column, and then further purified by semi-preparative HPLC to afford compounds **3** (46 mg, MeOH–H₂O,

49 : 51, *t_R* 23.9 min), **4** (5.0 mg, MeOH–H₂O, 35 : 65, *t_R* 12.2 min), **5** (8.0 mg, MeOH–H₂O, 25 : 75, *t_R* 19.5 min), **11** (3.0 mg, MeOH–H₂O, 60 : 40, *t_R* 12.9 min), **20** (13 mg, CH₃CN–H₂O, 35 : 65, *t_R* 11.7 min), **21** (23 mg, CH₃CN–H₂O, *t_R* 7.7 min), **22** (2.5 mg, CH₃CN–H₂O, 25 : 75, *t_R* 11.7 min), **23** (9 mg, MeOH–H₂O, 45 : 55, *t_R* 11.4 min), **24** (12 mg, MeOH–H₂O, 35 : 65, *t_R* 34.7 min), **27** (6.0 mg, MeOH–H₂O, 40 : 60, *t_R* 17.0 min), **28** (12 mg, CH₃CN–H₂O, 35 : 65, *t_R* 8.8 min), **29** (23 mg, CH₃CN–H₂O, 35 : 65, *t_R* 6.8 min), **30** (1.7 mg, MeOH–H₂O, 35 : 65, *t_R* 26.9 min), **31** (3 mg, CH₃CN–H₂O, 35 : 65, *t_R* 10.8 min).

3.4 Spectroscopic data

Isodonrubescins A (**1**): colorless needle crystals (MeOH); [α]_D = –107.8° (*c* 0.10, MeOH); UV (MeOH) λ_{\max} (log ϵ): 215 (2.48), 295 (1.58) nm; ¹H and ¹³C NMR data see Tables 1 and 2; HR-ESI-MS *m/z* 431.20383 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.20402).

Isodonrubescins B (**2**): colorless crystals (MeOH); [α]_D = –47.6° (*c* 0.01, MeOH); UV (MeOH) λ_{\max} (log ϵ): 205 (2.92) nm; ¹H and ¹³C NMR data see Tables 1 and 2; HR-ESI-MS *m/z* 431.20407 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.20402).

Isodonrubescins C (**3**): colorless crystals (MeOH); [α]_D = –101.0° (*c* 0.02, MeOH); UV (MeOH) λ_{\max} (log ϵ): 205 (3.21), 250 (2.43) nm; ¹H and ¹³C NMR data see Tables 1 and 2; HR-ESI-MS *m/z* 431.20288 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.20402).

Isodonrubescins D (**4**): white amorphous powder; [α]_D = +6.2° (*c* 0.03, MeOH); UV (MeOH) λ_{\max} (log ϵ): 210 (3.24), 250 (2.29) nm; ¹H and ¹³C NMR data see Tables 1 and 2; HR-ESI-MS *m/z* 431.20404 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.20402).

Isodonrubescins E (**5**): white amorphous powder; [α]_D = +9.1° (*c* 0.02, MeOH); UV (MeOH) λ_{\max} (log ϵ): 205 (3.29), 250 (2.86) nm; ¹H and ¹³C NMR data see Tables 1 and 2; HR-ESI-MS *m/z* 431.20380 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.20402).

Isodonrubescins F (**6**): white amorphous powder; [α]_D = +12.2° (*c* 0.02, MeOH); UV (MeOH) λ_{\max} (log ϵ): 210 (3.38) nm; ¹H and ¹³C NMR data see Tables 1 and 2; HR-ESI-MS *m/z* 349.20029 [M + H]⁺ (calcd for C₂₀H₂₉O₅, 349.20095).

3.5 NO production measurement and cell viability assay

The NO production and cell viability were determined by the Griess reaction and CCK-8 method respectively, which have been described in our previous paper.³⁸

4. Conclusions

In this study, six previously undescribed *ent*-kaurane diterpenoids, including two 6,7-*seco-ent*-kaurane diterpenoids (**1–2**), four 7,20-epoxy-*ent*-kaurane diterpenoids (**3–6**), together with twenty-five known *ent*-kaurane diterpenoids (**7–31**), a known *ent*-atisane diterpenoids (**32**), and two known *ent*-abietane diterpenoids (**33–34**) were isolated from *I. rubescens* collected from Badong county of Hubei Province, P. R. China. It was noteworthy that compounds **7** was isolated as a natural product for the first time, and *ent*-atisane diterpenoid was found from *I. rubescens* in Hubei Province for the first time. Among all the isolated compounds, 7,20-epoxy-*ent*-kaurane diterpenoids and 6,7-*seco-ent*-kaurane diterpenoids were the main chemical



constituents of *I. rubescens* collected from Hubei Province, which contained two types of diterpenoids isolated from *I. rubescens* collected from Henan and Guizhou Province, this may be related to the geographical location of Hubei Province lying between Henan and Guizhou Province. Moreover, all the isolated compounds were evaluated for their inhibitory effect against LPS induced nitric oxide production in RAW 264.7 macrophages. Compounds 7–9, 12, 13, 16, and 17 displayed obvious NO production inhibitory effects. In conclusion, those results have further facilitated our understanding of the active constituents of *I. rubescens* from Badong region and the potential bioactive constituents of *I. rubescens* accounting for the application as anti-inflammatory agents.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was financially supported by the National Major New Drugs Innovation and Development (2017ZX09301060), the National Key Research and Development Program of China (2018YFC1708004), the Special Fund for Basic Scientific Research of Central Colleges, South-Central University for Nationalities (CZP18004 and CZP17076) and the National Science Foundation of China (31600272).

References

- 1 H. D. Sun, S. X. Huang and Q. B. Han, *Nat. Prod. Rep.*, 2006, **23**, 673–698.
- 2 M. Liu, W. G. Wang, H. D. Sun and J. X. Pu, *Nat. Prod. Rep.*, 2017, **34**, 1090–1140.
- 3 A. Ohsaki, M. Ozawa, K. Komiyama, A. Kishida and T. Isobe, *Nat. Prod. Commun.*, 2012, **7**, 977–978.
- 4 X. M. Wang, C. X. Xie, S. L. Chen, H. Yao and J. P. Han, *J. Anhui Agric. Sci.*, 2008, **36**, 13677–13680.
- 5 L. L. Tian, D. L. Sheng, Q. H. Li, C. X. Guo and G. F. Zhu, *Pharm. Biol.*, 2019, **57**, 632–640.
- 6 F. L. Zhao, M. C. Sun, W. J. Zhang, C. L. Jiang, J. T. Teng, W. Sheng, M. Z. Li, A. M. Zhang, Y. B. Duan and J. P. Xue, *BMC Plant Biol.*, 2018, **18**, 272.
- 7 H. D. Sun, Z. W. Lin, F. D. Niu, L. Z. Lin, H. B. Chai, J. M. Pezzuto and G. A. Cordell, *Phytochemistry*, 1995, **38**, 437–442.
- 8 N. S. Bai, K. He, Z. Zhou, M. L. Tsai, L. Zhang, Z. Quan, X. Shao, M. H. Pan and C. T. Ho, *Planta Med.*, 2010, **76**, 140–145.
- 9 M. Hu, S. T. Xu and J. Y. Xu, *Pharmaceutical and Clinical Research*, 2017, **25**, 425–430.
- 10 W. C. Huang, M. C. Huang, H. Ouyang, J. W. Peng and J. Liang, *Eur. J. Pharmacol.*, 2018, **826**, 133–139.
- 11 Q. B. Han, Q. S. Zhao, S. H. Li, L. Y. Peng and H. D. Sun, *Acta Chim. Sin.*, 2003, **61**, 1077–1082.
- 12 Q. B. Han, R. T. Li, M. L. Li, Y. K. Mou, Q. E. Tian, S. W. Li and H. D. Sun, *J. Asian Nat. Prod. Res.*, 2005, **7**, 31–36.
- 13 X. Liu, Y. B. Xue, K. Dong, X. N. Li, Y. Li, J. X. Pu, J. Z. Wu and H. D. Sun, *Chin. J. Nat. Med.*, 2012, **10**, 464–470.
- 14 X. Liu, R. Zhan, W. G. Wang, X. Du, X. N. Li, J. H. Yang, P. Zhang, Y. Li, J. X. Pu, J. Z. Wu and H. D. Sun, *Chem. Pharm. Bull.*, 2013, **61**, 90–95.
- 15 X. Liu, W. G. Wang, X. Du, X. N. Li, L. M. Kong, Y. Li, J. X. Pu, J. Z. Wu and H. D. Sun, *Fitoterapia*, 2012, **83**, 1451–1455.
- 16 X. Liu, J. Yang, W. G. Wang, Y. Li, J. Z. Wu, J. X. Pu and H. D. Sun, *J. Nat. Prod.*, 2015, **78**, 196–201.
- 17 X. Liu, R. Zhan, W. G. Wang, X. Du, Y. Li, P. Zhang, J. X. Pu, J. Z. Wu and H. D. Sun, *Arch. Pharmacol. Res.*, 2012, **35**, 2147–2151.
- 18 J. W. Shu, F. Yuan, C. M. Wen and G. Z. Yang, *J. Green. Sci. Technol.*, 2017, **18**, 216–218.
- 19 J. X. Zhang, Z. A. He, Z. Y. Chen, Y. X. Wang, S. P. Bai and H. D. Sun, *J. Asian Nat. Prod. Res.*, 2009, **11**, 693–697.
- 20 X. M. Di and F. L. Yan, *Anhui Med. Pharm. J.*, 2013, **17**, 1470–1472.
- 21 S. Mori, K. Shudo, T. Ageta, T. Koizumi and T. Okamoto, *Chem. Pharm. Bull.*, 1970, **18**, 871–883.
- 22 N. Tanaka, E. Tsuji, K. Sakai, T. Gono and J. Kobayashi, *Phytochemistry*, 2014, **102**, 205–210.
- 23 E. Fujita, T. Fujita, Y. Okada, S. Nakamura and M. Shibuya, *Chem. Pharm. Bull.*, 1972, **20**, 2377–2383.
- 24 F. L. Yan, L. Q. Guo, S. P. Bai and H. D. Sun, *J. Chin. Chem. Soc.*, 2008, **55**, 933–936.
- 25 L. B. Yang, S. X. Huang, J. X. Pu and L. M. Li, *Res. Pract. Chin. Med.*, 2013, **20**, 25–29.
- 26 Y. Takeda, K. I. Takeda, T. Fujita, H. D. Sun and Y. Minami, *Phytochemistry*, 1994, **35**, 1513–1516.
- 27 W. Li, B. Li and Y. Chen, *Phytochemistry*, 1998, **49**, 2433–2435.
- 28 S. Mori, T. Koizumi, K. Shudo and T. Okamoto, *Chem. Pharm. Bull.*, 1970, **18**, 884–889.
- 29 Y. H. Gao, Z. X. Wei, Y. Cheng, T. H. Wang, L. Ni, X. H. Zhou and L. Y. Zhang, *Chem. Biodiversity*, 2013, **10**, 1487–1493.
- 30 Z. Hu, R. Zhang, X. Du, J. Su, X. N. Li and J. H. Yang, *Chem. Pharm. Bull.*, 2011, **59**, 1562–1566.
- 31 H. B. Zhang, J. X. Pu, Y. Y. Wang, F. He, Y. Zhao, X. N. Li, X. Luo, W. L. Xiao, Y. Li and H. D. Sun, *Chem. Pharm. Bull.*, 2010, **58**, 56–60.
- 32 Q. B. Han, M. L. Li, S. H. Li, Y. K. Mou, Z. W. Lin and H. D. Sun, *Chem. Pharm. Bull.*, 2003, **51**, 790–793.
- 33 F. Yin, J. Y. Liang and J. Liu, *J. China Pharm. Univ.*, 2003, **34**, 302–304.
- 34 H. D. Sun, Q. Zhou, T. Fujita, Y. Takeda, Y. Minami, T. Maronaka, Z. W. Lin and X. Y. Shen, *Phytochemistry*, 1992, **31**, 1418–1419.
- 35 R. Zhan, X. N. Li, X. Du, W. G. Wang, K. Dong, J. Su, Y. Li, J. X. Pu and H. D. Sun, *Fitoterapia*, 2013, **88**, 76–81.
- 36 W. Zhao, J. X. Pu, X. Du, J. Su, X. N. Li, J. H. Yang, Y. B. Xue, Y. Li and H. D. Sun, *Chin. J. Nat. Med.*, 2011, **9**, 253–258.
- 37 J. Wan, H. Y. Jiang, J. W. Tang, X. R. Li, X. Du, Y. Li, H. D. Sun and J. X. Pu, *Molecules*, 2017, **22**, 309–318.
- 38 H. D. Teng, Y. S. Ren, Z. Y. Ma, X. Tan, J. Xu, Y. Chen and G. Z. Yang, *Fitoterapia*, 2019, **137**, 104–245.

